What usage claims can FOXO4 currently support?
The specifications and research directions pending verification in the catalog can be explained, but this cannot be used to give a definite promise of effects in humans or animals. No. Natural proteins/genes and reversed D-peptides are different entities; only after confirming that the supplied sequence is consistent with FOXO4-DRI can the corresponding mouse senescent cell research be discussed.
No. Natural proteins/genes and reverse D-peptides are different entities; only after confirming that the supplied sequence is consistent with FOXO4-DRI can corresponding mouse senescent cell studies be discussed. This page is a curated collection of purpose-oriented positive data, not a systematic review or dosing recommendation. Historical studies, combination formulations, and special models are individually noted.
Qualified direct in vivo main literature has not yet been screened
No. Natural proteins/genes and reverse D-peptides are different entities; only after confirming that the supplied sequence is consistent with FOXO4-DRI can corresponding mouse senescent cell studies be discussed.
See common questions about this product ↓References
Supplement background1 article · not included in main in vivo literature
The following information is used to explain mechanisms, material identity, or evidence boundaries and cannot replace direct in vivo validation of the same product, formulation, and use.
What does FOXO4-DRI research on senescent cell clearance indicate?
Selectively acts on senescent cells and improves specific mouse physical performance, fur, and tissue functions.[1] ↗
FOXO4-DRI; studies in aging and chemotherapy-damaged mice including cell experiments
Only after confirming that the product is a FOXO4-DRI sequence is the association exist; Natural FOXO4 are not the same entity and do not prove the body's anti-aging properties.
View the Article Title and Full Citation＋
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
Cell · Volume and issue year 2017
First published 2017-03-23 · PMID 28340339
DOI 10.1016/j.cell.2017.02.031
Direct in vivo primary literature has not been included in this round; research status is mentioned above.
Common issues and corresponding evidence
Can FOXO4 and FOXO4-DRI be considered the same product?＋
No. Natural proteins/genes and reverse D-peptides are different entities; only after confirming that the supplied sequence is consistent with FOXO4-DRI can corresponding mouse senescent cell studies be discussed.[1] ↗
FOXO4 Why aren’t 3–5 efficacy papers listed?＋
At this stage, no sufficient qualified original studies have been screened that simultaneously correspond to commercial identity, main research purpose, and intervention form. Papers with similar names, single components, or other purposes cannot be used to supplement the data.
Current status of data / procurement verification, not efficacy conclusions.What materials are needed when reviewing FOXO4 study materials?＋
The full name, CAS or sequence, modifications/salt form, component ratio, source, and SKU batch COA should first be verified, then compared item by item with the paper materials.
Current status of data / procurement verification, not efficacy conclusions.FOXO4
Return to catalog specifications and batch file verification entry.
